Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Twelve-month findings showed favorable and consistent trends for participants receiving SKY-0515 across all four cUHDRS ...